

Gene Section

Short Communication

SULF2 (sulfatase 2)

Lewis Roberts, Chunling Hu

Division of Gastroenterology and Hepatology, Mayo Clinic and Mayo Clinic Cancer Center, Rochester, MN 55905, USA (LR, CH)

Published in Atlas Database: April 2013

Online updated version : <http://AtlasGeneticsOncology.org/Genes/SULF2ID43735ch20q13.html>
DOI: 10.4267/2042/51539

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2013 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity

Other names: HSULF-2

HGNC (Hugo): SULF2

Location: 20q13.12

DNA/RNA

Description

SULF2 55959 chr 20: 46286150-46415360. The gene encompasses 130 kb of DNA; 21 exons.

Transcription

3 transcripts: transcript variant 1, 3909 bp linear mRNA, 21 exons (NM_018837); transcript variant 2, 4239 bp linear mRNA, 21 exons (NM_198596); transcript variant 3, 4248 bp linear mRNA, 21 exons (NM_001161841).

Protein

Description

870 amino acid; 100 kDa protein; post translational modification: 11 N-glycosylation sites; contains from N-term to C-term, a signal peptide (1-24), a enzymatic domain (25-400) which contains a

conserved cysteine (88) essential for the catalytic activity, a hydrophilic domain (401-739) which contains four lysines and arginines rich domains suited for interactions with sulfated HSGAGs that fit the heparin-binding motif, and a glucosamine-6-sulfatase domain (740-870).

Expression


Widely expressed, especially in ovary, skeletal muscle, stomach, brain, uterus, heart, kidney, and placenta.

Localisation


Extracellular space, cell surface, plasma membrane, endoplasmic reticulum, and Golgi stack.

Function

SULF2 is a member of a novel family of extracellular HS 6-O endosulfatases with heparin-degrading endosulfatase activity. SULF2 desulfates HS and increases the local concentration of growth factors in the extracellular matrix. The released growth factors then bind to their cell surface receptors, with the consequent activation of cell growth and survival pathways in HCC. SULF2 up-regulated GPC3 expression and FGF2 ligand-receptor binding and signaling.



Schematic diagram of SULF2 with domains.



It has been shown that SULF2 liberates growth factors such as Wnt3a from HSPGs such as GPC3 on the cell surface and in the extracellular matrix by desulfating heparan sulfate (HS).

It has been reported that SULF2 mRNA is up-regulated in human breast cancers, and suppression of SULF2 expression decreases tumorigenesis of pancreatic cancer cell lines.

SULF2 regulates PDGFR α signaling and growth in malignant glioma.

Homology

Conserved in Rhesus monkey, dog, cow, mouse, rat, chicken, and zebrafish.

Mutations

Somatic

Identified mutations in various cancers.

Implicated in

Hepatocellular carcinoma (HCC)

Prognosis

In a microarray experiment performed on paired benign and tumor tissues from HCC patients, SULF2 expression was higher in the tumors than in the benign tissues in 79 (57%) of 139 HCCs. Patients with tumors expressing high SULF2 levels had a significantly poorer prognosis than those with tumor expressing low SULF2 levels (Lai et al., 2008a).

Oncogenesis

Expression of SULF2 promotes HCC cell proliferation and migration. Knockdown of SULF2 decreases HCC cell proliferation and migration. SULF2 promotes tumorigenesis in nude mice and up-regulates GPC3 in vivo (Lai et al., 2008a).

Lung cancer

Prognosis

Paired samples of lung squamous carcinoma and non malignant neighboring tissue were obtained from 10 patients undergoing surgical resection. SULF2

increased in 8/10 pairs with a mean increase of 3 ± 0.3 -fold. qPCR analysis of SULF2 in

archived cases of lung carcinoma verified it. SULF2 increased 4 ± 0.3 fold in squamous carcinomas and 3 ± 0.4 fold in adenocarcinomas (Lemjabbar-Alaoui et al., 2010).

Oncogenesis

Knockdown of SULF2 or expression of dominant-negative SULF2 reduces growth of lung cancer cells. SULF2 over-expression in non-malignant bronchial epithelial cells induces a transformed phenotype in culture.

SULF2 knockdown reduces growth of tumors arising from lung cancer cells (Lemjabbar-Alaoui et al., 2010).

Glioblastoma (GBM)

Prognosis

SULF2 expression is elevated in GBM. Using a stringent cutoff of a 10-fold increase in SULF2 SAGE tags over levels in normal brain to define high SULF2 levels, 7 of 16 GBMs has increased SULF2 expression. Strikingly, in an independent set of 424 primary human GBM tumors, SULF2 expression was increased in 46% (197/424) of tumors related to normal brain.

Immunohistochemistry on an independent set of 57 primary human GBM tumors demonstrated SULF2 protein in tumor cells in 50% of tumors.

SULF2 expression is associated with the proneural subtype of GBM characterized by abnormalities in the PDGFR α -signaling pathway and SULF2 expression is associated with the proneural GBM subtype (Phillips et al., 2012).

Oncogenesis

SULF2 confers a growth advantage to human GBM cells, SULF2 knockdown resulted in a significant decrease in cell viability.

SULF2 also confers a growth advantage to human GBM cells in vivo. SULF2 confers increased tumorigenicity and proliferation.

Prolonged survival conferred by ablation of SULF2 in tumorigenic neurospheres.

And absence of SULF2 resulted in decreased tumor cell proliferation in vivo (Phillips et al., 2012).

Breakpoint number	Rearrangement type	Cytoband translocation	Breakpoint junction	Data source	Associated Genes
8	Intra-chrm translocation	20q13.13-20q13.13	51 bp insert	BAC & Cell lines	Fusion ARFGEF2-SULF2

Breakpoints

Note

Fusion of ARFGEF2 exon 1 to SULF2 exons 3-21.

References

- Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. *J Biol Chem*. 2002 Dec 20;277(51):49175-85
- Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, Venkataraman G, Sasisekharan R, Sanderson RD. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. *J Biol Chem*. 2005 Dec 2;280(48):40066-73
- Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, Werb Z, Rosen SD. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. *Neoplasia*. 2005 Nov;7(11):1001-10
- Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z, Rosen SD. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. *BMC Biochem*. 2006 Jan 17;7:2
- Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS, Roberts LR. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. *Hepatology*. 2008a Apr;47(4):1211-22
- Lai JP, Thompson JR, Sandhu DS, Roberts LR. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. *Future Oncol*. 2008b Dec;4(6):803-14
- Lamanna WC, Frese MA, Balleininger M, Dierks T. Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. *J Biol Chem*. 2008 Oct 10;283(41):27724-35
- Otsuki S, Taniguchi N, Grogan SP, D'Lima D, Kinoshita M, Lotz M. Expression of novel extracellular sulfatases Sulf-1 and Sulf-2 in normal and osteoarthritic articular cartilage. *Arthritis Res Ther*. 2008;10(3):R61
- Chau BN, Diaz RL, Saunders MA, Cheng C, Chang AN, Warrener P, Bradshaw J, Linsley PS, Cleary MA. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. *Cancer Res*. 2009 Feb 15;69(4):1368-74
- Tang R, Rosen SD. Functional consequences of the subdomain organization of the sulfs. *J Biol Chem*. 2009 Aug 7;284(32):21505-14
- Lai JP, Oseini AM, Moser CD, Yu C, Elsawa SF, Hu C, Nakamura I, Han T, Aderca I, Isomoto H, Garrity-Park MM, Shire AM, Li J, Sanderson SO, Adjei AA, Fernandez-Zapico ME, Roberts LR. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. *Hepatology*. 2010a Nov;52(5):1680-9
- Lai JP, Sandhu DS, Yu C, Moser CD, Hu C, Shire AM, Aderca I, Murphy LM, Adjei AA, Sanderson S, Roberts LR. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. *Liver Int*. 2010b Nov;30(10):1522-8
- Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, He B, Jablons DM, Rosen SD. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. *Oncogene*. 2010 Feb 4;29(5):635-46
- Peterson SM, Iskenderian A, Cook L, Romashko A, Tobin K, Jones M, Norton A, Gómez-Yafal A, Heartlein MW, Concino MF, Liaw L, Martini PG. Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts. *BMC Cancer*. 2010 Aug 13;10:427
- Bret C, Moreaux J, Schved JF, Hose D, Klein B. SULFs in human neoplasia: implication as progression and prognosis factors. *J Transl Med*. 2011 May 21;9:72
- Gill RB, Day A, Barstow A, Liu H, Zaman G, Dhoot GK. Sulf2 gene is alternatively spliced in mammalian developing and tumour tissues with functional implications. *Biochem Biophys Res Commun*. 2011 Oct 28;414(3):468-73
- Staples GO, Shi X, Zaia J. Glycomics analysis of mammalian heparan sulfates modified by the human extracellular sulfatase HSulf2. *PLoS One*. 2011 Feb 8;6(2):e16689
- Yang JD, Sun Z, Hu C, Lai J, Dove R, Nakamura I, Lee JS, Thorgeirsson SS, Kang KJ, Chu IS, Roberts LR. Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. *Genes Chromosomes Cancer*. 2011 Feb;50(2):122-35
- Phillips JJ, Huillard E, Robinson AE, Ward A, Lum DH, Polley MY, Rosen SD, Rowitch DH, Werb Z. Heparan sulfate sulfatase SULF2 regulates PDGFR α signaling and growth in human and mouse malignant glioma. *J Clin Invest*. 2012 Mar 1;122(3):911-22

This article should be referenced as such:

Roberts L, Hu C. SULF2 (sulfatase 2). *Atlas Genet Cytogenet Oncol Haematol*. 2013; 17(10):713-715.